Varun Garg

533 total citations
18 papers, 397 citations indexed

About

Varun Garg is a scholar working on Oncology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Varun Garg has authored 18 papers receiving a total of 397 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Molecular Biology and 3 papers in Infectious Diseases. Recurrent topics in Varun Garg's work include Chronic Lymphocytic Leukemia Research (3 papers), Systemic Lupus Erythematosus Research (3 papers) and HIV/AIDS drug development and treatment (3 papers). Varun Garg is often cited by papers focused on Chronic Lymphocytic Leukemia Research (3 papers), Systemic Lupus Erythematosus Research (3 papers) and HIV/AIDS drug development and treatment (3 papers). Varun Garg collaborates with scholars based in United States, India and Greece. Varun Garg's co-authors include William J. Jusko, Ene Ette, Matthew W. Harding, Rolf van Heeswijk, Peter G. Rose, Kenneth D. Swenerton, Danielle Charpentier, Gerald Batist, Ursula A. Matulonis and Michael V. Seiden and has published in prestigious journals such as Blood, Gastroenterology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Varun Garg

17 papers receiving 388 citations

Peers

Varun Garg

ONCOL

HEPAT

EPIDE

Yoon Hwan Chang South Korea

Yusei Ikeda Japan

Masato Horikawa Japan

Anja Lautem Germany

Riko Ichikawa Japan

Malaz Abutarif United States

Nanya Wang China

Nathan D. Pfeifer United States

Aniska A. Chhatta Netherlands

Yoon Hwan Chang South Korea

Varun Garg

118 ×0.7

ONCOL

241 ×2.6

46 ×0.6

HEPAT

43 ×0.6

99 ×1.8

EPIDE

Citations per year, relative to Varun Garg Varun Garg (= 1×) peers Yoon Hwan Chang

Countries citing papers authored by Varun Garg

Since Specialization

Citations

This map shows the geographic impact of Varun Garg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Varun Garg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Varun Garg more than expected).

Fields of papers citing papers by Varun Garg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Varun Garg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Varun Garg. The network helps show where Varun Garg may publish in the future.

Co-authorship network of co-authors of Varun Garg

This figure shows the co-authorship network connecting the top 25 collaborators of Varun Garg. A scholar is included among the top collaborators of Varun Garg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Varun Garg. Varun Garg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Agarwal, Anil, et al.. (2024). Choi IIIB sequelae of septic hip: Etiologically different entities clubbed together?. Journal of Clinical Orthopaedics and Trauma. 53. 102469–102469.

Treon, Steven P., Christian Buske, Sheeba K. Thomas, et al.. (2021). Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations. Blood. 138(Supplement 1). 1362–1362. 11 indexed citations

Dale, David C., Steven P. Treon, David F. McDermott, et al.. (2021). Oral Administration of Mavorixafor, a CXCR4 Antagonist, Increases Peripheral White Blood Cell Counts across Different Disease States. Blood. 138(Supplement 1). 2186–2186. 4 indexed citations

Garg, Varun & Ankit Parakh. (2020). Spirometry vs Impulse oscillometry in evaluation of children with asthma. 2647–2647. 2 indexed citations

Dale, David C., Frank Firkin, Audrey Anna Bolyard, et al.. (2020). Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood. 136(26). 2994–3003. 38 indexed citations

Garg, Varun, Chonghua Li, Sagar Agarwal, et al.. (2019). Pharmacokinetic and Drug–Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor. Clinical and Translational Science. 12(3). 267–275. 29 indexed citations

Gordon, Stuart C., Andrew J. Muir, Varun Garg, & Joshua W. Henshaw. (2012). 835 Exposure-Response Relationships in Telaprevir Combination Therapy in Treatment-NaïVE Genotype 1 Chronic HCV Patients. Gastroenterology. 142(5). S–931. 1 indexed citations

Luo, Xia, et al.. (2012). Effect of Telaprevir on the Pharmacokinetics of Buprenorphine in Volunteers on Stable Buprenorphine/Naloxone Maintenance Therapy. Antimicrobial Agents and Chemotherapy. 56(7). 3641–3647. 23 indexed citations

Gordon, Stuart C., Andrew J. Muir, Varun Garg, & Joshua Henshaw. (2012). 1116 EXPOSURE-RESPONSE RELATIONSHIPS IN TELAPREVIR COMBINATION THERAPY IN TREATMENT-NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS. Journal of Hepatology. 56. S440–S440. 2 indexed citations

10.

Garg, Varun, et al.. (2011). The Pharmacokinetic Interaction Between an Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone and the HCV Protease Inhibitor Telaprevir. The Journal of Clinical Pharmacology. 52(10). 1574–1583. 26 indexed citations

11.

Adiwijaya, Bambang S., Tara L. Kieffer, Doug J. Bartels, et al.. (2011). Modeling, Clinical and Virology Data From Phase 2 and 3 Studies Support 12-Week Telaprevir Duration in Combination With 24- or 48-Week Peginterferon/Ribavirin. Gastroenterology. 140(5). S–943. 1 indexed citations

12.

Heeswijk, Rolf van, Pieter Verboven, Griet Boogaerts, et al.. (2011). 1244 THE PHARMACOKINETIC INTERACTION BETWEEN METHADONE AND THE INVESTIGATIONAL HCV PROTEASE INHIBITOR TELAPREVIR. Journal of Hepatology. 54. S491–S492. 26 indexed citations

13.

Heeswijk, Rolf van, Griet Boogaerts, Els De Paepe, et al.. (2011). 1245 THE EFFECT OF SEVERE RENAL IMPAIRMENT ON THE PHARMACOKINETICS OF THE INVESTIGATIONAL HCV PROTEASE INHIBITOR TELAPREVIR. Journal of Hepatology. 54. S492–S492. 12 indexed citations

14.

Rago, Randall, Albert Einstein, Richard M. Lush, et al.. (2003). Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Cancer Chemotherapy and Pharmacology. 51(4). 297–305. 25 indexed citations

15.

Toppmeyer, Deborah, Andrew D. Seidman, Michaël Pollak, et al.. (2002). Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.. PubMed. 8(3). 670–8. 61 indexed citations

16.

Seiden, Michael V., Kenneth D. Swenerton, Ursula A. Matulonis, et al.. (2002). A Phase II Study of the MDR Inhibitor Biricodar (INCEL, VX-710) and Paclitaxel in Women with Advanced Ovarian Cancer Refractory to Paclitaxel Therapy. Gynecologic Oncology. 86(3). 302–310. 80 indexed citations

17.

Garg, Varun & William J. Jusko. (1994). Bioavailability and reversible metabolism of prednisone and prednisolone in man. Biopharmaceutics & Drug Disposition. 15(2). 163–172. 54 indexed citations

18.

Garg, Varun, et al.. (1993). Respiratory Morbidity And Pulmonary Function Impairment In 'Solderers' : An Occupational Hazard In Modern Electronics. Lung India. 11(4). 143. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact